دورية أكاديمية
أعرض في EDS

B cells are associated with survival and immunotherapy response in sarcoma.

التفاصيل البيبلوغرافية
العنوان: B cells are associated with survival and immunotherapy response in sarcoma.
المؤلفون: Petitprez F; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France.; Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France., de Reyniès A; Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France., Keung EZ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chen TW; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; National Taiwan University Cancer Center, Taipei, Taiwan.; Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan., Sun CM; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Calderaro J; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Département de Pathologie, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Henri Mondor, Creteil, France.; Institut Mondor de Recherche Biomédicale, Creteil, France., Jeng YM; Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.; Department of Pathology, National Taiwan University, Taipei, Taiwan., Hsiao LP; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Lacroix L; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Bougoüin A; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Moreira M; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Lacroix G; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Natario I; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Adam J; Department of Biology and Pathology, Gustave Roussy, Villejuif, France., Lucchesi C; Institut Bergonié, Bordeaux, France.; Bioinformatics Unit, Institut Bergonié, Bordeaux, France., Laizet YH; Institut Bergonié, Bordeaux, France.; Bioinformatics Unit, Institut Bergonié, Bordeaux, France., Toulmonde M; Institut Bergonié, Bordeaux, France.; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Burgess MA; Department of Medicine, Divison of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA., Bolejack V; Cancer Research and Biostatistics, Seattle, WA, USA., Reinke D; Sarcoma Alliance for Research Through Collaboration, Ann Arbor, MI, USA., Wani KM; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roland CL; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Italiano A; Institut Bergonié, Bordeaux, France.; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.; University of Bordeaux, Bordeaux, France., Sautès-Fridman C; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Tawbi HA; Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. htawbi@mdanderson.org., Fridman WH; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France. herve.fridman@crc.jussieu.fr.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France. herve.fridman@crc.jussieu.fr.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France. herve.fridman@crc.jussieu.fr.
المصدر: Nature [Nature] 2020 Jan; Vol. 577 (7791), pp. 556-560. Date of Electronic Publication: 2020 Jan 15.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
أسماء مطبوعة: Publication: Basingstoke : Nature Publishing Group
Original Publication: London, Macmillan Journals ltd.
مواضيع طبية MeSH: Immunotherapy*, B-Lymphocytes/*immunology , Sarcoma/*drug therapy , Sarcoma/*immunology , Tertiary Lymphoid Structures/*immunology, Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; CD8-Positive T-Lymphocytes/immunology ; Cohort Studies ; Dendritic Cells, Follicular/immunology ; Humans ; Mutation ; Phenotype ; Prognosis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Reproducibility of Results ; Sarcoma/classification ; Sarcoma/pathology ; Survival Rate ; Tumor Microenvironment
مستخلص: Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes 1,2 . The clinical presentation of patients with different subtypes is often atypical, and responses to therapies such as immune checkpoint blockade vary widely 3,4 . To explain this clinical variability, here we study gene expression profiles in 608 tumours across subtypes of soft-tissue sarcoma. We establish an immune-based classification on the basis of the composition of the tumour microenvironment and identify five distinct phenotypes: immune-low (A and B), immune-high (D and E), and highly vascularized (C) groups. In situ analysis of an independent validation cohort shows that class E was characterized by the presence of tertiary lymphoid structures that contain T cells and follicular dendritic cells and are particularly rich in B cells. B cells are the strongest prognostic factor even in the context of high or low CD8 + T cells and cytotoxic contents. The class-E group demonstrated improved survival and a high response rate to PD1 blockade with pembrolizumab in a phase 2 clinical trial. Together, this work confirms the immune subtypes in patients with soft-tissue sarcoma, and unravels the potential of B-cell-rich tertiary lymphoid structures to guide clinical decision-making and treatments, which could have broader applications in other diseases.
التعليقات: Comment in: Nature. 2020 Jan;577(7791):474-476. (PMID: 31965091)
Comment in: Nat Rev Clin Oncol. 2020 Apr;17(4):195. (PMID: 32024979)
References: Helman, L. J. & Meltzer, P. Mechanisms of sarcoma development. Nat. Rev. Cancer 3, 685–694 (2003). (PMID: 10.1038/nrc1168)
Fletcher, C., Bridge, J., Hogendoorn, P. & Mertens, F. WHO Classification of Tumours of Soft Tissue and Bone (World Health Organization, 2013).
D’Angelo, S. P. et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 19, 416–426 (2018). (PMID: 10.1016/S1470-2045(18)30006-8)
Tawbi, H. A. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18, 1493–1501 (2017). (PMID: 10.1016/S1470-2045(17)30624-1)
Beck, A. H. et al. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene 29, 845–854 (2010). (PMID: 10.1038/onc.2009.381)
Gibault, L. et al. New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J. Pathol. 223, 64–71 (2011). (PMID: 10.1002/path.2787)
Pollack, S. M. et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer 123, 3291–3304 (2017). (PMID: 10.1002/cncr.30726)
Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950–965.e28 (2017). (PMID: 10.1016/j.cell.2017.10.014)
Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016). (PMID: 10.1186/s13059-016-1070-5)
Burgess, M. A. et al. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): final results of SARC028 expansion cohorts. JCO 37, 11015–11015 (2019). (PMID: 10.1200/JCO.2019.37.7_suppl.393)
Kroeger, D., Milne, K. & H Nelson, B. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clinical Cancer Res. 22, 3005–3015 (2016). (PMID: 10.1158/1078-0432.CCR-15-2762)
Sautès-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307–325 (2019). (PMID: 10.1038/s41568-019-0144-6)
Coppola, D. et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179, 37–45 (2011). (PMID: 10.1016/j.ajpath.2011.03.007)
Dieu-Nosjean, M.-C., Goc, J., Giraldo, N. A., Sautès-Fridman, C. & Fridman, W. H. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 35, 571–580 (2014). (PMID: 10.1016/j.it.2014.09.006)
Posch, F. et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. OncoImmunology 7, e1378844 (2017). (PMID: 10.1080/2162402X.2017.1378844)
Siliņa, K. et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 78, 1308–1320 (2018). (PMID: 10.1158/0008-5472.CAN-17-1987)
Gu-Trantien, C. et al. CD4 + follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123, 2873–2892 (2013). (PMID: 10.1172/JCI67428)
Dorfman, D. M., Brown, J. A., Shahsafaei, A. & Freeman, G. J. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 30, 802–810 (2006). (PMID: 10.1097/01.pas.0000209855.28282.ce)
D’Angelo, S. P. et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum. Pathol. 46, 357–365 (2015). (PMID: 10.1016/j.humpath.2014.11.001)
Sorbye, S. W. et al. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin. Pathol. 12, 5 (2012). (PMID: 10.1186/1472-6890-12-5)
Sorbye, S. W. et al. High expression of CD20 + lymphocytes in soft tissue sarcomas is a positive prognostic indicator. OncoImmunology 1, 75–77 (2012). (PMID: 10.4161/onci.1.1.17825)
Bertucci, F. et al. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. OncoImmunology 6, e1278100 (2017). (PMID: 10.1080/2162402X.2016.1278100)
Kim, J. R. et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 8, e82870 (2013). (PMID: 10.1371/journal.pone.0082870)
Honda, Y. et al. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. OncoImmunology 6, e1253657 (2016). (PMID: 10.1080/2162402X.2016.1253657)
Paydas, S., Bagir, E. K., Deveci, M. A. & Gonlusen, G. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med. Oncol. 33, 93 (2016). (PMID: 10.1007/s12032-016-0807-z)
Nielsen, J. S. et al. CD20 + tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8 + T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18, 3281–3292 (2012). (PMID: 10.1158/1078-0432.CCR-12-0234)
Montfort, A. et al. A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin. Cancer Res. 23, 250–262 (2017). (PMID: 10.1158/1078-0432.CCR-16-0081)
Hennequin, A. et al. Tumor infiltration by Tbet + effector T cells and CD20 + B cells is associated with survival in gastric cancer patients. OncoImmunology 5, e1054598 (2015). (PMID: 10.1080/2162402X.2015.1054598)
Wouters, M. C. A. & Nelson, B. H. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 24, 6125–6135 (2018). (PMID: 10.1158/1078-0432.CCR-18-1481)
Helmink, B. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature https://doi.org/10.1038/s41586-019-1922-8  (2020). (PMID: 10.1038/s41586-019-1922-8)
Chibon, F. et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat. Med. 16, 781–787 (2010). (PMID: 10.1038/nm.2174)
Barretina, J. et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 42, 715–721 (2010). (PMID: 10.1038/ng.619)
Gobble, R. M. et al. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. Cancer Res. 71, 2697–2705 (2011). (PMID: 10.1158/0008-5472.CAN-10-3588)
Lagarde, P. et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin. Cancer Res. 18, 826–838 (2012). (PMID: 10.1158/1078-0432.CCR-11-1610)
Lagarde, P. et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J. Clin. Oncol. 31, 608–615 (2013). (PMID: 10.1200/JCO.2012.46.0147)
McCall, M. N., Bolstad, B. M. & Irizarry, R. A. Frozen robust multiarray analysis (fRMA). Biostatistics 11, 242–253 (2010). (PMID: 10.1093/biostatistics/kxp059)
Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118–127 (2007). (PMID: 10.1093/biostatistics/kxj037)
Petitprez, F. et al. Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunol. Immunother. 67, 981–988 (2017). (PMID: 10.1007/s00262-017-2058-z)
Beuselinck, B. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 21, 1329–1339 (2015). (PMID: 10.1158/1078-0432.CCR-14-1128)
Giraldo, N. A. et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21, 3031–3040 (2015). (PMID: 10.1158/1078-0432.CCR-14-2926)
معلومات مُعتمدة: T32 CA009599 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Antibodies, Monoclonal, Humanized)
0 (PDCD1 protein, human)
0 (Programmed Cell Death 1 Receptor)
DPT0O3T46P (pembrolizumab)
تواريخ الأحداث: Date Created: 20200117 Date Completed: 20200507 Latest Revision: 20230325
رمز التحديث: 20231215
DOI: 10.1038/s41586-019-1906-8
PMID: 31942077
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-4687
DOI:10.1038/s41586-019-1906-8